Trial Profile
A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy; Liver cirrhosis
- Focus Pharmacodynamics
- Acronyms RIFSYS
- 24 Sep 2021 Results published in the Journal of Hepatology
- 26 Jun 2021 Primary endpoint (Rifaximin- reducing neutrophil spontaneous oxidative burst ex vivo) has been met, according to Results presented at The International Liver Congress 2021.
- 26 Jun 2021 Results presented at The International Liver Congress 2021